Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Long-Term Debt Repayments (2018 - 2023)

Endonovo Therapeutics has reported Long-Term Debt Repayments over the past 7 years, most recently at $20000.0 for Q3 2023.

  • Quarterly results put Long-Term Debt Repayments at $20000.0 for Q3 2023, changed N/A from a year ago — trailing twelve months through Sep 2023 was $35000.0 (changed N/A YoY), and the annual figure for FY2020 was $22000.0, down 83.08%.
  • Long-Term Debt Repayments for Q3 2023 was $20000.0 at Endonovo Therapeutics, roughly flat from $20000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for ENDV hit a ceiling of $140000.0 in Q1 2019 and a floor of -$10000.0 in Q2 2019.
  • Median Long-Term Debt Repayments over the past 3 years was $14000.0 (2021), compared with a mean of $28833.3.
  • Peak annual rise in Long-Term Debt Repayments hit 4334.59% in 2019, while the deepest fall reached 207.03% in 2019.
  • Endonovo Therapeutics' Long-Term Debt Repayments stood at -$10000.0 in 2019, then soared by 50.0% to -$5000.0 in 2021, then surged by 500.0% to $20000.0 in 2023.
  • The last three reported values for Long-Term Debt Repayments were $20000.0 (Q3 2023), $20000.0 (Q1 2023), and -$5000.0 (Q3 2021) per Business Quant data.